logo-loader
RNS
Craneware PLC

Craneware plc - FY26 Trading Update

RNS Number : 8784K
Craneware plc
03 July 2026
 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a Regulatory Information Service, this information is considered to be in the public domain.

 

03 July 2026

Craneware plc

("Craneware" or the "Company")

 

FY26 Trading Update

 

Craneware (AIM: CRW.L), a leader in healthcare financial performance solutions, provides the following update on trading for the financial year ended 30 June 2026 ("FY26").

 

The Board expects the Group's FY26 financial performance to be below market expectations, with revenue of US$205-$208 million and Adjusted EBITDA of US$65-$67 million, both broadly in line with FY25. This change results from the timing of eligible 340B activity and the deferral of a small number of significant enterprise contracts, which are now expected to contribute during FY27. The final reported outcome remains subject to confirmation of eligible 340B activity recognised before the financial year end.

 

Customer retention, customer demand and cash generation have remained strong throughout the year. Trading in the final weeks of FY26 was materially impacted by a slower than anticipated conversion of identified 340B opportunities into recognised revenue. Craneware continues to identify substantial opportunities for hospitals to optimise their 340B programs; with outstanding 340B qualifying drug purchases in the region of $500m, however, the pace at which those opportunities translated into eligible drug purchases slowed significantly as pharmaceutical manufacturers further expanded and operationalised restrictions on the supply of certain 340B-priced medicines.

 

The Group recognises a significant proportion of this revenue upon the customer receiving the benefit from these eligible 340B drugs, rather than at the point opportunities are identified. The financial impact of this reduced conversion only became apparent once the actual amount of 340B drugs shipped to the hospitals before year end became clear.

 

The Board believes that these factors reflect a short-term timing impact to the FY26 results. Looking ahead, customer demand is increasingly extending beyond software and analytics towards technology-enabled operational transformation that helps healthcare providers realise the opportunities identified by the Group's platform. Craneware has been developing these capabilities over the last three years and they now represent a meaningful and growing component of the Group's offering. This reinforces, rather than diminishes, the long-term strategic importance of Craneware's platform within the evolving US healthcare ecosystem.

 

The combination of Craneware's trusted data, technology, AI enabled workflows and people, collectively expands the Group's technology-enabled operational capabilities, positioning Craneware to support customers in navigating an increasingly complex healthcare environment and realise greater financial value from their operations.

 

The Board will provide a further update with the announcement of the Group's full year results in September 2026.

 

Keith Neilson, CEO of Craneware plc, commented,

 

 "Naturally we are disappointed not to have delivered the growth that we expected in FY26. While the short-term complexity in the pharmacy market has impacted the year, the long-term opportunity remains intact.

 

"This reinforces our strategy of expanding beyond software and analytics into technology-enabled operational transformation that helps customers realise the opportunities identified by the Group's platform, and this is a continuing area of focus for our innovation efforts. We believe this strengthens both our customer relationships and our long-term growth opportunity, as healthcare providers increasingly seek trusted partners capable of combining data, workflow automation and operational expertise to deliver measurable financial outcomes. Our role is evolving from helping customers identify opportunity to helping them realise it.

 

"We continue to benefit from high levels of customer retention and cash generation, providing us with a strong financial foundation to execute on our strategy."  

 

For further information, please contact:

 

Craneware plc

+44 (0)131 550 3100

Keith Neilson, CEO


Craig Preston, CFO




Alma Strategic Communications

+44 (0)20 3405 0205

Caroline Forde, Louisa El-Ahwal

craneware@almastrategic.com



Peel Hunt (NOMAD and Joint Broker) 

+44 (0)20 7418 8900

Neil Patel, Benjamin Cryer, Kate Bannatyne




Investec Bank PLC (Joint Broker)

+44 (0)20 7597 5970

Patrick Robb, Virginia Bull, Arnav Kapoor


  

 

Berenberg (Joint Broker)

+44 (0)20 3207 7800

Mark Whitmore, Tom Ballard, Patrick Dolaghan, Ryan Mahnke


 

About Craneware

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster - that simplify the complexities of healthcare finance and operations. What sets us apart is our unique combination of deep healthcare expertise and engineering excellence, positioning us as a strategic partner rather than just a technology provider. The Craneware Group empowers healthcare organizations to achieve sustainable financial success while delivering better outcomes for the communities they serve - today and in the future. Together, we are transforming the business of healthcare.

 

Learn more at www.thecranewaregroup.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKBBBDBKBCOK
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read